Carfilzomib

Carfilzomib (PR-171) is a definitive, cell-permeable, irreversible tetrapeptide epoxyketone proteasome inhibitor that selectively targets the chymotrypsin-like (ChT-L) activity of the constitutive 20S proteasome (β5) and immunoproteasome (LMP7/β5i) with nanomolar potency (IC50 < 5 nM). By forming specific morpholino adducts with catalytic N-terminal threonines, PR-171 decouples pharmacokinetics from pharmacodynamics, ensuring sustained target suppression despite rapid systemic clearance (t1/2 < 30 min). Unlike boronic acid predecessors, the epoxyketone exhibits negligible affinity for non-proteasomal serine proteases (e.g., cathepsin G, elastase), resulting in a superior neurotoxicity profile. Mechanistically, Carfilzomib blocks NF-κB signaling via IκBα stabilization and drives the accumulation of poly-ubiquitinated proteins, precipitating catastrophic ER stress, mitochondrial depolarization, and JNK-mediated apoptosis. Clinically validated for relapsed/refractory multiple myeloma, PR-171 overcomes bortezomib resistance and demonstrates profound synergy with dexamethasone, lenalidomide and daratumumab in high-risk phenotypes.